Atto BioScience Raises $3M in Series A Financing | GenomeWeb

NEW YORK, Oct. 29 – Atto BioScience, a Rockville, Md.-based biotech company,  has raised $3 million in its first round of private equity financing, the company said on Monday.

Emerging Technology Partners led the financing round.

The capital will help Atto to finish the development and commercialization of its first high-throughput single-cell-imaging system. This system, scheduled to launch later this year, was developed in collaboration with a major US pharmaceutical company, Atto said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.